Selected research
Industry Research
Oral Anti-allergic Drugs Industry Research Report 2026
Market perspective
The global Oral Anti-allergic Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Oral Anti-allergic Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Oral Anti-allergic Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Oral Anti-allergic Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Oral Anti-allergic Drugs include Chongqing Huapont Pharmaceutical, Yangtze River Pharmaceutical Group, Teva, Sun Pharma, Sanofi, Johnson & Johnson, Hainan Poly Pharm, Novartis and Merck, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Oral Anti-allergic Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Oral Anti-allergic Drugs Market by Company
Chongqing Huapont Pharmaceutical
Yangtze River Pharmaceutical Group
Teva
Sun Pharma
Sanofi
Johnson & Johnson
Hainan Poly Pharm
Novartis
Merck
Pfizer
GlaxoSmithKline
Dawnrays Pharma
Bayer
AstraZeneca
UCB Pharma
Boehringer Ingelheim
Almirall
Oral Anti-allergic Drugs Segment by Type
Immunosuppressant Drugs
Antihistamine Drugs
Allergic Mediator Release Agent
Oral Anti-allergic Drugs Segment by Application
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Oral Anti-allergic Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oral Anti-allergic Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Oral Anti-allergic Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oral Anti-allergic Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Oral Anti-allergic Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Oral Anti-allergic Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Oral Anti-allergic Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Immunosuppressant Drugs
- Antihistamine Drugs
- Allergic Mediator Release Agent
Applications
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
Companies covered
- Chongqing Huapont Pharmaceutical
- Yangtze River Pharmaceutical Group
- Teva
- Sun Pharma
- Sanofi
- Johnson & Johnson
- Hainan Poly Pharm
- Novartis
- Merck
- Pfizer
- GlaxoSmithKline
- Dawnrays Pharma
- Bayer
- AstraZeneca
- UCB Pharma
- Boehringer Ingelheim
- Almirall
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Oral Anti-allergic Drugs Market Size (2021-2032)
- 2.2.2 Global Oral Anti-allergic Drugs Sales (2021-2032)
- 2.2.3 Global Oral Anti-allergic Drugs Market Average Price (2021-2032)
- 2.3 Oral Anti-allergic Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Immunosuppressant Drugs
- 2.3.3 Antihistamine Drugs
- 2.3.4 Allergic Mediator Release Agent
- 2.4 Oral Anti-allergic Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital Pharmacies
- 2.4.3 Online Pharmacies
- 2.4.4 Retail Pharmacies
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Oral Anti-allergic Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Oral Anti-allergic Drugs Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Oral Anti-allergic Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Oral Anti-allergic Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Oral Anti-allergic Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Oral Anti-allergic Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Oral Anti-allergic Drugs, Product Type & Application
- 3.8 Global Manufacturers of Oral Anti-allergic Drugs, Established Date
- 3.9 Global Oral Anti-allergic Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Chongqing Huapont Pharmaceutical
- 4.1.1 Chongqing Huapont Pharmaceutical Company Information
- 4.1.2 Chongqing Huapont Pharmaceutical Business Overview
- 4.1.3 Chongqing Huapont Pharmaceutical Oral Anti-allergic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Chongqing Huapont Pharmaceutical Oral Anti-allergic Drugs Product Portfolio
- 4.1.5 Chongqing Huapont Pharmaceutical Recent Developments
- 4.2 Yangtze River Pharmaceutical Group
- 4.2.1 Yangtze River Pharmaceutical Group Company Information
- 4.2.2 Yangtze River Pharmaceutical Group Business Overview
- 4.2.3 Yangtze River Pharmaceutical Group Oral Anti-allergic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Yangtze River Pharmaceutical Group Oral Anti-allergic Drugs Product Portfolio
- 4.2.5 Yangtze River Pharmaceutical Group Recent Developments
- 4.3 Teva
- 4.3.1 Teva Company Information
- 4.3.2 Teva Business Overview
- 4.3.3 Teva Oral Anti-allergic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Teva Oral Anti-allergic Drugs Product Portfolio
- 4.3.5 Teva Recent Developments
- 4.4 Sun Pharma
- 4.4.1 Sun Pharma Company Information
- 4.4.2 Sun Pharma Business Overview
- 4.4.3 Sun Pharma Oral Anti-allergic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Sun Pharma Oral Anti-allergic Drugs Product Portfolio
- 4.4.5 Sun Pharma Recent Developments
- 4.5 Sanofi
- 4.5.1 Sanofi Company Information
- 4.5.2 Sanofi Business Overview
- 4.5.3 Sanofi Oral Anti-allergic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Sanofi Oral Anti-allergic Drugs Product Portfolio
- 4.5.5 Sanofi Recent Developments
- 4.6 Johnson & Johnson
- 4.6.1 Johnson & Johnson Company Information
- 4.6.2 Johnson & Johnson Business Overview
- 4.6.3 Johnson & Johnson Oral Anti-allergic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Johnson & Johnson Oral Anti-allergic Drugs Product Portfolio
- 4.6.5 Johnson & Johnson Recent Developments
- 4.7 Hainan Poly Pharm
- 4.7.1 Hainan Poly Pharm Company Information
- 4.7.2 Hainan Poly Pharm Business Overview
- 4.7.3 Hainan Poly Pharm Oral Anti-allergic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Hainan Poly Pharm Oral Anti-allergic Drugs Product Portfolio
- 4.7.5 Hainan Poly Pharm Recent Developments
- 4.8 Novartis
- 4.8.1 Novartis Company Information
- 4.8.2 Novartis Business Overview
- 4.8.3 Novartis Oral Anti-allergic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Novartis Oral Anti-allergic Drugs Product Portfolio
- 4.8.5 Novartis Recent Developments
- 4.9 Merck
- 4.9.1 Merck Company Information
- 4.9.2 Merck Business Overview
- 4.9.3 Merck Oral Anti-allergic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Merck Oral Anti-allergic Drugs Product Portfolio
- 4.9.5 Merck Recent Developments
- 4.10 Pfizer
- 4.10.1 Pfizer Company Information
- 4.10.2 Pfizer Business Overview
- 4.10.3 Pfizer Oral Anti-allergic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Pfizer Oral Anti-allergic Drugs Product Portfolio
- 4.10.5 Pfizer Recent Developments
- 4.11 GlaxoSmithKline
- 4.11.1 GlaxoSmithKline Company Information
- 4.11.2 GlaxoSmithKline Business Overview
- 4.11.3 GlaxoSmithKline Oral Anti-allergic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 GlaxoSmithKline Oral Anti-allergic Drugs Product Portfolio
- 4.11.5 GlaxoSmithKline Recent Developments
- 4.12 Dawnrays Pharma
- 4.12.1 Dawnrays Pharma Company Information
- 4.12.2 Dawnrays Pharma Business Overview
- 4.12.3 Dawnrays Pharma Oral Anti-allergic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Dawnrays Pharma Oral Anti-allergic Drugs Product Portfolio
- 4.12.5 Dawnrays Pharma Recent Developments
- 4.13 Bayer
- 4.13.1 Bayer Company Information
- 4.13.2 Bayer Business Overview
- 4.13.3 Bayer Oral Anti-allergic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Bayer Oral Anti-allergic Drugs Product Portfolio
- 4.13.5 Bayer Recent Developments
- 4.14 AstraZeneca
- 4.14.1 AstraZeneca Company Information
- 4.14.2 AstraZeneca Business Overview
- 4.14.3 AstraZeneca Oral Anti-allergic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 AstraZeneca Oral Anti-allergic Drugs Product Portfolio
- 4.14.5 AstraZeneca Recent Developments
- 4.15 UCB Pharma
- 4.15.1 UCB Pharma Company Information
- 4.15.2 UCB Pharma Business Overview
- 4.15.3 UCB Pharma Oral Anti-allergic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 UCB Pharma Oral Anti-allergic Drugs Product Portfolio
- 4.15.5 UCB Pharma Recent Developments
- 4.16 Boehringer Ingelheim
- 4.16.1 Boehringer Ingelheim Company Information
- 4.16.2 Boehringer Ingelheim Business Overview
- 4.16.3 Boehringer Ingelheim Oral Anti-allergic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 Boehringer Ingelheim Oral Anti-allergic Drugs Product Portfolio
- 4.16.5 Boehringer Ingelheim Recent Developments
- 4.17 Almirall
- 4.17.1 Almirall Company Information
- 4.17.2 Almirall Business Overview
- 4.17.3 Almirall Oral Anti-allergic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.17.4 Almirall Oral Anti-allergic Drugs Product Portfolio
- 4.17.5 Almirall Recent Developments
5 Global Oral Anti-allergic Drugs Market Scenario by Region
- 5.1 Global Oral Anti-allergic Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Oral Anti-allergic Drugs Sales by Region: 2021-2032
- 5.2.1 Global Oral Anti-allergic Drugs Sales by Region: 2021-2026
- 5.2.2 Global Oral Anti-allergic Drugs Sales by Region: 2027-2032
- 5.3 Global Oral Anti-allergic Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Oral Anti-allergic Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Oral Anti-allergic Drugs Revenue by Region: 2027-2032
- 5.4 North America Oral Anti-allergic Drugs Market Facts & Figures by Country
- 5.4.1 North America Oral Anti-allergic Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Oral Anti-allergic Drugs Sales by Country (2021-2032)
- 5.4.3 North America Oral Anti-allergic Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Oral Anti-allergic Drugs Market Facts & Figures by Country
- 5.5.1 Europe Oral Anti-allergic Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Oral Anti-allergic Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Oral Anti-allergic Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Oral Anti-allergic Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Oral Anti-allergic Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Oral Anti-allergic Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Oral Anti-allergic Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Oral Anti-allergic Drugs Market Facts & Figures by Country
- 5.7.1 South America Oral Anti-allergic Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Oral Anti-allergic Drugs Sales by Country (2021-2032)
- 5.7.3 South America Oral Anti-allergic Drugs Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Oral Anti-allergic Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Oral Anti-allergic Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Oral Anti-allergic Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Oral Anti-allergic Drugs Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Oral Anti-allergic Drugs Sales by Type (2021-2032)
- 6.1.1 Global Oral Anti-allergic Drugs Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Oral Anti-allergic Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Oral Anti-allergic Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Oral Anti-allergic Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Oral Anti-allergic Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Oral Anti-allergic Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Oral Anti-allergic Drugs Sales by Application (2021-2032)
- 7.1.1 Global Oral Anti-allergic Drugs Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Oral Anti-allergic Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Oral Anti-allergic Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Oral Anti-allergic Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Oral Anti-allergic Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Oral Anti-allergic Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Oral Anti-allergic Drugs Value Chain Analysis
- 8.1.1 Oral Anti-allergic Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Oral Anti-allergic Drugs Production Mode & Process
- 8.2 Oral Anti-allergic Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Oral Anti-allergic Drugs Distributors
- 8.2.3 Oral Anti-allergic Drugs Customers
9 Global Oral Anti-allergic Drugs Analyzing Market Dynamics
- 9.1 Oral Anti-allergic Drugs Industry Trends
- 9.2 Oral Anti-allergic Drugs Industry Drivers
- 9.3 Oral Anti-allergic Drugs Industry Opportunities and Challenges
- 9.4 Oral Anti-allergic Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst